Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MENOPUR vs BRAVELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Menotropins (MENOPUR) contain follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity, which stimulate ovarian follicular growth and maturation in women, and spermatogenesis in men with hypogonadotropic hypogonadism.
Bravelle (urofollitropin) is a purified preparation of follicle-stimulating hormone (FSH) that stimulates ovarian follicular growth and maturation by binding to FSH receptors on granulosa cells, increasing c AMP production and promoting follicular development.
Induction of ovulation in patients with polycystic ovary syndrome (PCOS) after failure of clomiphene citrate,Controlled ovarian hyperstimulation for assisted reproductive technologies (ART) such as in vitro fertilization (IVF),Off-label: Treatment of male hypogonadotropic hypogonadism (in combination with human chorionic gonadotropin)
Ovulation induction in anovulatory women with polycystic ovary syndrome (PCOS),Controlled ovarian hyperstimulation for assisted reproductive technologies (ART) such as in vitro fertilization (IVF)
225 IU subcutaneously or intramuscularly once daily starting on day 2-3 of cycle, adjusted after 5 days based on response; maximum daily dose 450 IU.
For ovulation induction: 150 IU subcutaneously or intramuscularly once daily for 5 days, starting on day 3 or 5 of menstrual cycle. For controlled ovarian hyperstimulation: 150-225 IU subcutaneously or intramuscularly once daily for 5-7 days, then adjust based on response.
The terminal elimination half-life is approximately 30-40 hours for FSH activity, reflecting the prolonged effect on follicular development; clinical dosing is adjusted based on response.
Terminal elimination half-life approximately 5-6 hours in healthy adults. Extended in renal impairment (up to 24 hours with Cr Cl <30 m L/min).
Metabolism is not fully characterized; renally excreted as intact protein.
Primarily metabolized in the liver via renal excretion; metabolic pathways not fully characterized.
Primarily renal excretion of unchanged drug and metabolites; approximately 80% of a dose is excreted in urine within 24 hours, with the remainder excreted in feces via biliary elimination.
Primarily renal: 95% of administered dose excreted unchanged in urine within 24 hours. Biliary/fecal: 5% eliminated via feces.
Approximately 10-20% bound to plasma proteins, primarily albumin.
Approximately 10-20% bound to plasma proteins (albumin and α-1 acid glycoprotein).
Approximately 0.5-0.6 L/kg, indicating distribution primarily into extracellular fluid and limited tissue binding.
Approximately 0.3-0.5 L/kg. Distributing primarily in extracellular fluid; does not extensively penetrate tissues.
Subcutaneous or intramuscular: Approximately 70-80% due to partial local degradation; oral bioavailability is negligible (<1%).
Subcutaneous: 90-95% bioavailable relative to intramuscular route. Oral: not clinically used due to enzymatic degradation.
No specific guidelines; use with caution in severe renal impairment (GFR <30 m L/min) due to limited data, consider risk of fluid retention.
No specific guidelines exist for GFR-based dose modifications; use with caution in severe renal impairment (Cr Cl <30 m L/min) and monitor for adverse effects.
No specific guidelines; contraindicated in severe hepatic impairment (Child-Pugh class C) as metabolism is hepatic; use with caution in Child-Pugh class B.
No specific guidelines exist for Child-Pugh based modifications; use with caution in severe hepatic impairment and monitor for adverse effects.
Not indicated; no established pediatric dosing.
Not indicated for use in pediatric patients; safety and efficacy not established.
Not indicated for geriatric patients; no dosing recommendations.
Not indicated for use in geriatric patients; safety and efficacy not established.
MENOPUR should only be used by physicians who are experienced in infertility diagnosis and management. Use may cause ovarian hyperstimulation syndrome (OHSS), which can be severe and result in pulmonary embolism, stroke, ovarian torsion, or death. Use should be avoided in women with a high baseline FSH level indicating primary ovarian failure.
Bravelle should only be used by physicians who are experienced in infertility treatment and can manage potential serious adverse events, including ovarian hyperstimulation syndrome (OHSS) and multiple gestations.
Ovarian Hyperstimulation Syndrome (OHSS) - risk minimized by monitoring estradiol levels and ultrasound; discontinue if severe.,Multiple pregnancy - high risk; counseling is required.,Ovarian enlargement - usually resolves without treatment.,Pulmonary embolism and arterial thromboembolism - especially in severe OHSS.,Ovarian torsion - consider in patients with severe OHSS.,Ectopic pregnancy - increased risk in patients with tubal disease.,Congenital malformations - incidence similar to natural conception.,Ovarian neoplasms - no definitive causal link, but caution.
Ovarian enlargement and ovarian hyperstimulation syndrome (OHSS) – can lead to serious complications; discontinue treatment if OHSS is suspected.,Multiple gestations – increased risk of multiple births.,Ovarian torsion – report sudden abdominal pain.,Pulmonary and vascular complications – thromboembolic events; discontinue if suspected.,Ectopic pregnancy and spontaneous abortion – higher rates in ART patients.,Neoplasms – risk of ovarian neoplasms with repeated use.
Hypersensitivity to menotropins or any component.,High baseline FSH indicating primary ovarian failure.,Uncontrolled thyroid or adrenal dysfunction.,Organic intracranial lesion (e.g., pituitary tumor).,Abnormal uterine bleeding of undetermined origin.,Ovarian cysts or enlargement of undetermined origin (not due to PCOS).,Sex hormone-dependent tumors (e.g., ovarian, breast, uterine).,Pregnancy and lactation.
Hypersensitivity to urofollitropin or any component,High levels of FSH indicating primary ovarian failure,Uncontrolled thyroid or adrenal dysfunction,Known or suspected pregnancy,Ovarian cyst or enlargement of undetermined origin,Abnormal uterine bleeding of undetermined origin,Sex hormone-dependent tumors (e.g., breast, uterus, ovary)
No clinically relevant food interactions have been reported. Patients should maintain a normal balanced diet. Grapefruit and grapefruit juice are not known to interact with menotropins. No restriction on caffeine or dairy products.
No known food interactions. Maintain normal diet and hydration. Avoid alcohol as it may exacerbate side effects like nausea.
Menopur (menotropins) is a gonadotropin preparation used for ovulation induction. Fetal risk in the first trimester is associated with an increased incidence of neural tube defects, congenital heart defects, and multiple anomalies, likely related to the underlying infertility and assisted reproductive technology rather than direct teratogenicity. Second and third trimester risks include preterm labor, low birth weight, and perinatal mortality due to multiple gestation and ovarian hyperstimulation syndrome (OHSS).
Pregnancy Category X. Urofollitropin is contraindicated in pregnant women due to risk of fetal harm. First trimester: Ovarian hyperstimulation syndrome (OHSS) and multiple gestations. Second and third trimesters: No direct fetal effects reported, but risks associated with multiple gestation (preterm birth, low birth weight). Maternal OHSS may lead to thromboembolism.
Menotropins are not indicated during lactation due to lack of data. It is unknown if menotropins are excreted in human milk. Because of the potential for serious adverse reactions in nursing infants, breastfeeding should be discontinued during therapy. M/P ratio is unknown.
Urofollitropin is not indicated for use during lactation. No data on excretion in human milk, M/P ratio not established. Use during breastfeeding is contraindicated due to potential for adverse effects on infant hormone levels.
Menopur is contraindicated during pregnancy. If inadvertent exposure occurs, no dose adjustment is applicable as therapy is discontinued upon pregnancy confirmation. Pharmacokinetic changes in pregnancy (increased plasma volume, altered hormone levels) are not relevant since the drug is not used during gestation.
No dose adjustment applicable as therapy is discontinued upon confirmed pregnancy. No pharmacokinetic data during pregnancy; drug is not used after conception due to contraindication.
MENOPUR (menotropins) is a purified preparation of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) used for ovulation induction and controlled ovarian stimulation. Monitor ovarian response with ultrasound and estradiol levels to minimize risk of ovarian hyperstimulation syndrome (OHSS). Adjust dose based on antral follicle count and prior response. For IVF, concomitant gonadotropin-releasing hormone (Gn RH) antagonist or agonist is typically used to prevent premature LH surge. Administer intramuscularly or subcutaneously; reconstitute immediately before use. Multifetal pregnancy rates are high; counsel patients accordingly.
BRAVELLE (urofollitropin) is a purified FSH product used for controlled ovarian hyperstimulation. Administer subcutaneously; rotate injection sites. Monitor estradiol levels and follicle growth via ultrasound. Risk of ovarian hyperstimulation syndrome (OHSS); consider using Gn RH antagonist protocols to reduce risk. Do not administer if patient has high baseline FSH levels (>15 IU/L) indicating poor ovarian reserve.
MENOPUR is a hormone injection used to help your ovaries produce multiple eggs. It is given as a shot under the skin or into a muscle. Your doctor will show you how to prepare and inject the medication. Do not shake the vial after mixing. Use each vial only once and discard any unused medicine.,Common side effects include injection site reactions (pain, redness, swelling), ovarian enlargement, abdominal discomfort, and mood swings. Serious risks include ovarian hyperstimulation syndrome (OHSS) with symptoms like sudden severe abdominal pain, nausea, vomiting, and rapid weight gain. Notify your doctor immediately if you experience these.,You will have frequent blood tests and vaginal ultrasounds to monitor your response. Stick to the schedule and do not change doses without consulting your doctor.,There is a high chance of multiple pregnancy (twins, triplets, etc.). Discuss the risks and implications with your doctor.,Avoid alcohol and smoking during treatment. No specific food restrictions, but maintain a balanced diet to support overall health.
Teach proper injection technique and site rotation (abdomen, thigh).,Report immediately if severe pelvic pain, nausea, vomiting, or rapid weight gain occurs (OHSS signs).,Avoid intercourse until instructed to prevent multiple pregnancy.,Inform of multiple pregnancy risk (especially twins).,Store vials in refrigerator (2-8°C) and protect from light.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MENOPUR vs BRAVELLE, answered by our medical review team.
MENOPUR is a Gonadotropin that works by Menotropins (MENOPUR) contain follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity, which stimulate ovarian follicular growth and maturation in women, and spermatogenesis in men with hypogonadotropic hypogonadism.. BRAVELLE is a Gonadotropin that works by Bravelle (urofollitropin) is a purified preparation of follicle-stimulating hormone (FSH) that stimulates ovarian follicular growth and maturation by binding to FSH receptors on granulosa cells, increasing c AMP production and promoting follicular development.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MENOPUR and BRAVELLE depend on the specific clinical indication. These are both Gonadotropin agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MENOPUR is: 225 IU subcutaneously or intramuscularly once daily starting on day 2-3 of cycle, adjusted after 5 days based on response; maximum daily dose 450 IU.. The standard adult dose of BRAVELLE is: For ovulation induction: 150 IU subcutaneously or intramuscularly once daily for 5 days, starting on day 3 or 5 of menstrual cycle. For controlled ovarian hyperstimulation: 150-225 IU subcutaneously or intramuscularly once daily for 5-7 days, then adjust based on response.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MENOPUR and BRAVELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MENOPUR is classified as Category C. Menopur (menotropins) is a gonadotropin preparation used for ovulation induction. Fetal risk in the first trimester is associated with an increased incidence of neural tube defects. BRAVELLE is classified as Category C. Pregnancy Category X. Urofollitropin is contraindicated in pregnant women due to risk of fetal harm. First trimester: Ovarian hyperstimulation syndrome (OHSS) and multiple gestatio. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.